Cancer Antibodies: Drug Target Atlas and Competitive Outlook

Published by: BioSeeker Group AB

Published: Nov. 1, 2012 - 2361 Pages

Table of Contents

1 Executive Summary

2 About Cancer Highlights™

2.1 Cancer Focus Areas

2.2 Subscribe Today and Start Saving

2.2.1 Type of License

2.3 Additional Information

2.4 BioSeeker Group’s Oncology Team

3 Methodology

3.1 Cancer Highlights’™ Five Pillar Drug Assessment

4 Table of Contents

4.1 List of Figures

4.2 List of Tables

5 Introduction

5.1 The Scope of this Report

5.2 Definitions

5.3 Abbreviations

6 Consider the Therapeutic Target Among Antibody Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment

6.1 Drug Repositioning in Oncology

6.2 Introduction to Targets of Antibody Drugs in Cancer

6.2.1 Antigen Binding Targets

6.2.2 ATPase Activity Targets

6.2.3 Auxiliary Transport Protein Activity Targets

6.2.4 B Cell Receptor Activity Targets

6.2.5 Binding Targets

6.2.6 Carboxypeptidase Activity Targets

6.2.7 Catalytic Activity Targets

6.2.8 Cell Adhesion Molecule Activity Targets

6.2.9 Chaperone Activity Targets

6.2.10 Chemokine Activity Targets

6.2.11 Cofactor Binding Targets

6.2.12 Complement Activity Targets

6.2.13 Cysteine-type Peptidase Activity Targets

6.2.14 Cytokine Activity Targets

6.2.15 Defense/Immunity Protein Activity Targets

6.2.16 DNA Topoisomerase Activity Targets

6.2.17 Extracellular Ligand-gated Ion Channel Activity Targets

6.2.18 Extracellular Matrix Structural Constituent Targets

6.2.19 G-protein Coupled Receptor Activity Targets

6.2.20 Growth Factor Activity Targets

6.2.21 Guanylate Cyclase Activity Targets

6.2.22 Hormone Activity Targets

6.2.23 Hydrolase Activity Targets

6.2.24 Intracellular Ligand-gated Ion Channel Activity Targets

6.2.25 Kinase Binding Targets

6.2.26 Metallopeptidase Activity Targets

6.2.27 MHC Class I Receptor Activity Targets

6.2.28 Molecular Function Unknown Targets

6.2.29 Oxidoreductase Activity Targets

6.2.30 Peptidase Activity Targets

6.2.31 Peptide Hormone Targets

6.2.32 Protease Inhibitor Activity Targets

6.2.33 Protein Binding Targets

6.2.34 Protein Serine/Threonine Kinase Activity Targets

6.2.35 Receptor Activity Targets

6.2.36 Receptor Binding Targets

6.2.37 Receptor Signaling Complex Scaffold Activity Targets

6.2.38 Receptor Signaling Protein Serine/Threonine Kinase Activity Targets

6.2.39 Receptor Signaling Protein Tyrosine Phosphatase Activity Targets

6.2.40 RNA-directed DNA Polymerase Activity Targets

6.2.41 Serine-type Peptidase Activity Targets

6.2.42 Structural Constituent of Cytoskeleton Targets

6.2.43 Structural Molecule Activity Targets

6.2.44 T Cell Receptor Activity Targets

6.2.45 Transcription Factor Activity Targets

6.2.46 Transcription Regulator Activity Targets

6.2.47 Translation Regulator Activity Targets

6.2.48 Transmembrane Receptor Activity Targets

6.2.49 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets

6.2.50 Transporter Activity Targets

6.2.51 Other Targets

6.3 Mutation Profiles of Antibody Drug Targets in Oncology

6.3.1 Targets of Antibody Drugs in Cancer Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer

6.4 Antibody Therapeutics is Stimulated by Available Structure Data on Targets

6.5 Target-Target Interactions among Identified Targets of Antibody Drugs in Cancer

6.6 Protein Expression Levels of Identified Targets of Antibody Drugs in Cancer

6.7 The Drug-Target Competitive Landscape

6.8 Pathway Assessment of Antibody Drugs in Cancer

6.8.1 Tools for Analysis of Cancer Pathways

6.8.2 Pathway Assessment

7 Emerging Drug Candidates to Established Ones: Drug Target Strategies of Antibody Drugs in Cancer by their Highest Stage of Development

7.1 Pre-registrered and Marketed: New and Unique Drug Target Strategies of Antibody Drugs in Cancer

7.2 Phase III Clinical Development: New and Unique Drug Target Strategies of Antibody Drugs in Cancer

7.3 Phase II Clinical Development: New and Unique Drug Target Strategies of Antibody Drugs in Cancer

7.4 Phase I Clinical Development: New and Unique Drug Target Strategies of Antibody Drugs in Cancer

7.5 Preclinical Development: New and Unique Drug Target Strategies of Antibody Drugs in Cancer

7.6 Drug Target Strategies of Suspended or Terminated Antibody Drugs in Cancer

7.7 Target Strategy Development Profiles of Antibody Drugs in Cancer

7.7.1 Marketed

7.7.2 Phase III

7.7.3 Phase II

7.7.4 Phase I

7.7.5 Preclinical

7.7.6 Suspended

7.7.7 Ceased

7.8 The Competition Through Close Mechanistic Approximation of Antibody Drugs in Cancer

8 Selecting Indication for Antibody Drugs in Oncology

8.1 Acute Lymphocytic Leukemia

8.2 Acute Myelogenous Leukemia

8.3 B-cell Lymphoma

8.4 Basal Cell Cancer

8.5 Biliary Cancer

8.6 Bladder Cancer

8.7 Bone Cancer

8.8 Brain Cancer

8.9 Breast Cancer

8.10 Cancer (general)

8.11 Carcinoid Tumors

8.12 Cervical Cancer

8.13 Chronic Lymphocytic Leukemia

8.14 Chronic Myelogenous Leukemia

8.15 Chronic Myelomonocytic Leukemia

8.16 CNS Cancer

8.17 Colorectal Cancer

8.18 Endometrial Cancer

8.19 Esophageal Cancer

8.20 Ewing's Sarcoma

8.21 Fallopian Tube Cancer

8.22 Gastrointestinal Cancer (general)

8.23 Gastrointestinal Stomach Cancer

8.24 Gastrointestinal Stromal Cancer

8.25 Genitourinary Cancer

8.26 Glioma

8.27 Hairy Cell Leukemia

8.28 Head and Neck Cancer

8.29 Hematological Cancer (general)

8.30 Hodgkin's Lymphoma

8.31 Leiomyo Sarcoma

8.32 Leukemia (general)

8.33 Liver Cancer

8.34 Lung Cancer (general)

8.35 Lymphoma (general)

8.36 Malignant ascites

8.37 Melanoma

8.38 Merkel Cell Carcinoma

8.39 Mesothelioma

8.40 Myelodysplastic Syndrome

8.41 Myeloma

8.42 Nasopharyngeal Cancer

8.43 Neuroblastoma

8.44 Neuroectodermal Sarcoma

8.45 Neuroendocrine Cancer (general)

8.46 non-Hodgkin's Lymphoma

8.47 Non-Small Cell Lung Cancer

8.48 Oesophageal Cancer

8.49 Oral Cancer

8.50 Osteo Sarcoma

8.51 Ovarian Cancer

8.52 Pancreatic Cancer

8.53 Peritoneal Cancer

8.54 Pituitary Adenoma

8.55 Prostate Cancer

8.56 Renal Cancer

8.57 Rhabdomyo Sarcoma

8.58 Sarcoma (general)

8.59 Skin Appendage Cancer

8.60 Skin Cancer (general)

8.61 Small Cell Lung Cancer

8.62 Soft Tissue Sarcoma

8.63 Solid Tumor

8.64 Squamous Cell Cancer

8.65 Synovial Sarcoma

8.66 T-cell Lymphoma

8.67 Testicular Cancer

8.68 Thymoma Cancer

8.69 Thyroid Cancer

8.70 Unspecified Cancer Type

8.71 Vaccine adjunct

8.72 Waldenstrom's hypergammaglobulinemia

9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Antibody Drug Pipeline by Investigator

9.1 Changes in the Competitive Landscape: M&A, Bankruptcy and Name Change

9.2 Company Facts and Ranking

9.3 Competitive Fall-Out Assessment

9.4 A&G Pharmaceutical

9.5 Abbott

9.6 Abcam

9.7 Abiogen

9.8 Ablynx

9.9 AC Immune

9.10 Acceleron Pharma

9.11 Access

9.12 Actinium Pharmaceuticals

9.13 Active Biotech

9.14 Adherex

9.15 Affibody

9.16 Affimed Therapeutics

9.17 Affitech

9.18 AGY Therapeutics

9.19 Aida Pharmaceuticals

9.20 Alder Biopharmaceuticals

9.21 Alethia Biotherapeutics

9.22 Alexion

9.23 Algeta

9.24 ALSP

9.25 Altor BioScience

9.26 Amgen

9.27 Amorfix Life Sciences

9.28 Antisoma

9.29 Aphios

9.30 Apricus Biosciences

9.31 Arana Therapeutics

9.32 Arca biopharma

9.33 Areva

9.34 arGEN-X

9.35 Astellas

9.36 1AstraZeneca

9.37 AVEO

9.38 Bayer

9.39 Berkeley Lab

9.40 Biocon

9.41 Biogen Idec

9.42 BioInvent

9.43 Biolex

9.44 BioLineRx

9.45 Biosceptre

9.46 Biotecnol

9.47 Biotest

9.48 Boehringer Ingelheim

9.49 Bristol-Myers Squibb

9.50 BTG

9.51 Cancer Innovations

9.52 Cancer Research Technology

9.53 Celldex Therapeutics

9.54 Celltrion

9.55 Celtic Pharma

9.56 Center of Molecular Immunology

9.57 Centrose

9.58 CG Therapeutics

9.59 Circadian Technologies

9.60 CSL

9.61 CuraGen

9.62 CureTech

9.63 Customized Therapeutics

9.64 CytImmune Sciences

9.65 Daiichi Sankyo

9.66 Dendreon

9.67 DiaMedica

9.68 Dompe

9.69 Dr Reddy's

9.70 Dyax

9.71 Eisai

9.72 Elan

9.73 Eli Lilly

9.74 Emergent BioSolutions

9.75 Ergon Pharmaceuticals

9.76 EUSA Pharma

9.77 Expression Drug Designs

9.78 Fabrus

9.79 Faron Pharmaceuticals

9.80 Favrille

9.81 Femta Pharmaceuticals

9.82 FibroGen

9.83 Five Prime Therapeutics

9.84 Fusion Antibodies

9.85 Galaxy Biotech

9.86 GammaCan

9.87 Ganymed Pharmaceuticals

9.88 Gene Techno Science

9.89 Genencor

9.90 Genentech

9.91 Genmab

9.92 Genomic Systems

9.93 GenPat77

9.94 Gilead Sciences

9.95 GlaxoSmithKline

9.96 Gliknik

9.97 Glycotope

9.98 Green Cross

9.99 Hawthorn Pharmaceuticals

9.100 Hoffmann-La Roche

9.101 Human Genome Sciences

9.102 IDM Pharma

9.103 ImClone Systems

9.104 IMED

9.105 Immune Pharmaceuticals

9.106 ImmunoCellular Therapeutics

9.107 ImmunoGen

9.108 Immunomedics

9.109 Immutep

9.110 Innate Pharma

9.111 InNexus Biotechnology

9.112 Intracel

9.113 ISA Pharmaceuticals

9.114 ISU ABXIS

9.115 Johnson & Johnson

9.116 Kaketsuken

9.117 KaloBios

9.118 Kirin Pharma

9.119 Kissei

9.120 Kyowa Hakko Kirin

9.121 Kyto Biopharma

9.122 LFB Biotechnologies

9.123 LG Life Sciences

9.124 MacroGenics

9.125 MAT Biopharma

9.126 Medarex

9.127 MediGene

9.128 MedImmune

9.129 Menarini

9.130 Merck & Co

9.131 Merck KGaA

9.132 Merrimack

9.133 Micromet

9.134 Mitsubishi Tanabe Pharma

9.135 Mycenax

9.136 Neovacs

9.137 Neuren

9.138 NIH

9.139 NKT Therapeutics

9.140 Non-industrial Sources

9.141 Northwest Biotherapeutics

9.142 Novartis

9.143 OncoMed

9.144 OncoTherapy Science

9.145 Oncothyreon

9.146 Onyvax

9.147 Oxford BioMedica

9.148 Paladin Labs

9.149 Panacea

9.150 PanGenetics

9.151 Patrys

9.152 Pepscan Therapeutics

9.153 Peregrine Pharmaceuticals

9.154 Perseus Proteomics

9.155 Pfizer

9.156 PharmAbcine

9.157 Philogen

9.158 Pierre Fabre

9.159 Prima Biomed

9.160 PROBIOMED

9.161 ProCell Therapeutics

9.162 Prochon Biotech

9.163 Progenics Pharmaceuticals

9.164 Ramot

9.165 Recepta biopharma

9.166 Receptor BioLogix

9.167 Regeneron

9.168 Sanofi

9.169 SBI Biotech

9.170 Scancell

9.171 Seattle Genetics

9.172 Shanghai CP Guojian

9.173 Shenogen

9.174 Stainwei Biotech

9.175 Sunol Molecular

9.176 SuppreMol

9.177 Switch Pharma

9.178 Symphogen

9.179 Synageva BioPharma

9.180 SynerGene Therapeutics

9.181 Tactic Pharma

9.182 Takeda

9.183 Tamir Biotechnology

9.184 Targa Therapeutics

9.185 TeGenero

9.186 Teva

9.187 ThromboGenics

9.188 Titan Pharmaceuticals

9.189 Tolerx

9.190 Tracon Pharmaceuticals

9.191 Transgene

9.192 Trillium Therapeutics

9.193 Trion Pharma

9.194 UCB

9.195 United Therapeutics

9.196 Vaccinex

9.197 VasGene Therapeutics

9.198 Viragen

9.199 Viventia Biotech

9.200 Wakunaga

9.201 Wilex

9.202 XBiotech

9.203 Xencor

9.204 Xerion

9.205 Xoma

9.206 Y's Therapeutics

9.207 YM BioSciences

9.208 Zenotech

10 Disclaimer

1.1 List of Figures

Figure 1: Visualization of Target-Target Interactions among Targets of Antibody Drugs in Cancer

Figure 2: The Drug-Target Competitive Landscape of Antibody Drugs in Cancer - Large Cluster

Figure 3: The Drug-Target Competitive Landscape Antibody Drugs in Cancer - Smaller Clusters 1(2)

Figure 4: The Drug-Target Competitive Landscape Antibody Drugs in Cancer - Smaller Clusters 2(2)

Figure 5: Head-to-Head Targeting Competitive Landscape of Antibody Drugs in Cancer - 1 (2)

Figure 6: Head-to-Head Targeting Competitive Landscape of Antibody Drugs in Cancer - 2 (2)

Figure 7: Number of Companies per Ranking Level

1.2 List of Tables

Table 1: Cancer Highlights’™ Five Pillar Drug Assessment

Table 2: Breakdown of the Included Antibody Drug Pipeline in Oncology by Stage of Development

Table 3: Head to Head Target Competition among Antibody Drugs

Table 4: Overview of Drug Target Strategy Themes

Table 5: Ceased Targets of Antibody Drugs in Cancer

Table 6: Official Gene Symbol to Target Profle

Table 7: Mutation Frequencies of Antibody Drug Targets

Table 8: Identity of Drug Targets with Available Biological Structures

Table 9: Number of Target-Target Interactions among Targets of Antibody Drugs in Cancer

Table 10: Available Protein Expression Profiles of Antibody Drug Targets

Table 11: Pathway Summary

Table 12: Drug Targets without any Identified Assigned Pathways

Table 13: Pathway Profiles According to BioCarta of Antibody Drug Targets in Oncology

Table 14: Pathway Profiles According to KEGG of Antibody Drug Targets in Oncology

Table 15: Pathway Profiles According to NetPath of Antibody Drug Targets in Oncology

Table 16: Number of Drug Target Strategies by their Highest Developmental Stage and Uniqueness

Table 17: Top Competitive Target Strategies of Antibody Drugs in Cancer

Table 18: New and Unique Target Strategies of Antibody Drugs in Cancer in Pre-registration or on the Marketed

Table 19: The Competition Through Close Mechanistic Approximation Between Antibody Drugs in Cancer Being Marketed

Table 20: New and Unique Target Strategies in Phase III Clinical Development of Antibody Drugs in Cancer

Table 21: The Competition Through Close Mechanistic Approximation Between Phase III Antibody Drugs in Cancer

Table 22: New and Unique Target Strategies in Phase II Clinical Development of Antibody Drugs in Cancer

Table 23: The Competition Through Close Mechanistic Approximation Between Phase II Antibody Drugs in Cancer

Table 24: New and Unique Target Strategies in Phase I Clinical Development of Antibody Drugs in Cancer

Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Antibody Drugs in Cancer

Table 26: New and Unique Target Strategies in Preclinical Development of Antibody Drugs in Cancer

Table 27: The Competition Through Close Mechanistic Approximation Between Preclinical Antibody Drugs in Cancer

Table 28: Target Strategies of Suspended or Terminated Antibody Drugs in Cancer

Table 29: Connecting Target Strategy with Its Profile Identification Number

Table 30: The Competition Through Close Mechanistic Approximation Among Antibody Drugs in Cancer

Table 31 Competitive Summary by Cancer Indication of Antibody Drugs

Table 32: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Acute Lymphocytic Leukemia

Table 33: The Competition through Close Mechanistic Approximation between Acute Lymphocytic Leukemia Drugs

Table 34: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Acute Myelogenous Leukemia

Table 35: The Competition through Close Mechanistic Approximation between Acute Myelogenous Leukemia Drugs

Table 36: Target Strategy Development Profiles of Antibody Drugs for the Treatment of B-cell Lymphoma

Table 37: The Competition through Close Mechanistic Approximation between B-cell Lymphoma Drugs

Table 38: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Basal Cell Cancer

Table 39: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Biliary Cancer

Table 40: The Competition through Close Mechanistic Approximation between Biliary Cancer Drugs

Table 41: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Bladder Cancer

Table 42: The Competition through Close Mechanistic Approximation between Bladder Cancer Drugs

Table 43: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Bone Cancer

Table 44: The Competition through Close Mechanistic Approximation between Bone Cancer Drugs

Table 45: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Brain Cancer

Table 46: The Competition through Close Mechanistic Approximation between Brain Cancer Drugs

Table 47: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Breast Cancer

Table 48: The Competition through Close Mechanistic Approximation between Breast Cancer Drugs

Table 49: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Cancer (general)

Table 50: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Carcinoid Tumors

Table 51: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Cervical Cancer

Table 52: The Competition through Close Mechanistic Approximation between Cervical Cancer Drugs

Table 53: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Chronic Lymphocytic Leukemia

Table 54: The Competition through Close Mechanistic Approximation between Chronic Lymphocytic Leukemia Drugs

Table 55: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Chronic Myelogenous Leukemia

Table 56: The Competition through Close Mechanistic Approximation between Chronic Myelogenous Leukemia Drugs

Table 57: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Chronic Myelomonocytic Leukemia

Table 58: Target Strategy Development Profiles of Antibody Drugs for the Treatment of CNS Cancer

Table 59: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Colorectal Cancer

Table 60: The Competition through Close Mechanistic Approximation between Colorectal Cancer Drugs

Table 61: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Endometrial Cancer

Table 62: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Esophageal Cancer

Table 63: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Ewing's Sarcoma

Table 64 The Competition through Close Mechanistic Approximation between Ewing’s Sarcoma Drugs

Table 65: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Fallopian Tube Cancer

Table 66: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Gastrointestinal Cancer (general)

Table 67: The Competition through Close Mechanistic Approximation between Gastrointestinal Cancer (general) Drugs

Table 68: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Gastrointestinal Stomach Cancer

Table 69: The Competition through Close Mechanistic Approximation between Gastrointestinal Stomach Cancer Drugs

Table 70: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Gastrointestinal Stromal Cancer

Table 71: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Genitourinary Cancer

Table 72: The Competition through Close Mechanistic Approximation between Genitourinary Cancer Drugs

Table 73: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Glioma

Table 74: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Hairy Cell Leukemia

Table 75: The Competition through Close Mechanistic Approximation between Hairy Cell Leukemia Drugs

Table 76: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Head and Neck Cancer

Table 77: The Competition through Close Mechanistic Approximation between Head and Neck Cancer Drugs

Table 78: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Hematological Cancer (general)

Table 79: The Competition through Close Mechanistic Approximation between Hematological Cancer Drugs

Table 80: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Hodgkin's Lymphoma

Table 81: The Competition through Close Mechanistic Approximation between Hodgkin's Lymphoma Drugs

Table 82: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Leiomyo Sarcoma

Table 83: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Leukemia (general)

Table 84: The Competition through Close Mechanistic Approximation between Leukemia (general) Drugs

Table 85: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Liver Cancer

Table 86: The Competition through Close Mechanistic Approximation between Liver Cancer Drugs

Table 87: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Lung Cancer (general)

Table 88: The Competition through Close Mechanistic Approximation between Lung Cancer (general) Drugs

Table 89: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Lymphoma (general)

Table 90: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Malignant ascites

Table 91: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Melanoma

Table 92: The Competition through Close Mechanistic Approximation between Melanoma Drugs

Abstract

• Where the competition is; Which targets, tumor types and companies are setting the path?
• How much R&D effort has gone towards different targets and what is known about the target?
• Indication expansion opportunities
• Drug repositioning opportunities
• Which pathways are targeted, by what and how?
• What is truly new and unique in the antibody pipeline in cancer?
• How new and unique your target strategy really is
• Locate the right drugs to benchmark against and see were others may have succeeded or failed before you.

• Head-to-head target competing analysis
• Significant drug target overlap analysis
• Cross-sectional R&D profiling of individual drug targets.
• Cross-over analysis of target strategies among different tumor types.
• Competitive Fall-Out analysis of the entire company pipeline: Answering

-Where are we? -Where is our general and specific competition? -What is the level of competition where we want to be?

• Better identifying benchmarking peers
• Providing rationale for in/out licensing decisions of drug candidates
• Performing proper drug due diligence
• Strategies for commercial planning
• Guiding Research & Development efforts

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports, company profiles and country profiles from over 720 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.